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Trichomonas vaginalis causes vaginitis in women, 
urethritis in both sexes and is associated with signifi-
cant complications, including preterm delivery, low 
birth-weight and increased risk of HIV infection (1). 
Microscopical detection of T. vaginalis in wet-mount 
preparations of genital fluids may miss up to half of 
infections, and culture has a highly suboptimal sensiti-
vity compared with modern molecular diagnostic tests 
(1). Thus, nucleic acid amplification tests (NAATs), 
with a sensitivity and specificity of 95–100% (1), have 
revolutionized the diagnosis of trichomoniasis and are 
providing new insights into the epidemiology of the 
disease. Recent NAAT-based studies on women atten-
ding sexually transmitted diseases (STD) clinics have 
shown unexpectedly high prevalence rates (14.6–27%) 
of trichomoniasis in the USA (2, 3). In contrast, the 
prevalence in Western European countries and Australia 
appears to be substantially lower, i.e. 0.6–3.6% (4, 5). 
The prevalence of T. vaginalis infection in the Nordic 
countries in Northern Europe is largely unknown, with 
the exception of a single NAAT-based study in Sweden, 
where 1,121 consecutive STD clinic attendees in Örebro 
demonstrated prevalence rates of 0.16% in women and 
0% in men, using the APTIMA TV Assay (6). The aim 
of the present study was to examine the prevalence of T. 
vaginalis infection and selected STDs among consecutive 
Icelandic women attending an STD clinic and a cervical 
cancer screening programme.  
MATERIALS AND METHODS
From 1 February to 16 March 2016, consecutive women were 
recruited from the Department of Sexually Transmitted Diseases 
at Landspítali University Hospital (the only STD clinic in Ice-
land) and the Icelandic Cancer Society, both located in the capital 
area of Reykjavík, whose population is approximately 214,000 
individuals. All consecutive women who were 18 years of age 
or older at the STD clinic and between 35 and 64 years of age at 
the Cancer Society were invited to participate, and those who ac-
cepted provided written informed consent. Information about age 
distribution was available for STD clinic attendees only. The STD 
clinic collected urine specimens in the APTIMA Urine Specimen 
Transport Tubes (Hologic) from all participants for Chlamydia 
trachomatis and Neisseria gonorrhoeae APTIMA NAAT on the 
Tigris instrument (Hologic). High vaginal swabs were also col-
lected from women with genitourinary symptoms (e.g. abnormal 
vaginal discharge, vulvovaginal itch or burning, dyspareunia, or 
dysuria), for bacterial vaginosis test and yeast culture that were 
done by Nugent’s Gram stain method (7) and 5-day culture on 
Sabouraud dextrose agar with chloramphenicol. White, creamy 
and restricted colonies composed of non-arthroconidial yeast cells 
were presumptively identified as Candida species. The Cancer 
Society collected cervical smears into PreservCyt Solution liquid 
Pap (Cytic Corporation, Marlborough, MA, USA) and 1 ml of the 
liquid was subsequently transferred into the APTIMA Specimen 
Transfer Kit (Hologic). Due to lack of appropriate ethical appro-
val, women recruited at the Cancer Society could not be tested 
for infections other than trichomoniasis. Urine specimens, after 
C. trachomatis and N. gonorrhoeae testing, and cervical smear 
liquids were stored at –80°C for 4 months prior to testing for T. 
vaginalis, which was done by the use of APTIMA TV Assay on 
the Panther instrument (Hologic). The study was approved by the 
National Bioethics Committee (permission no. 14-161).
RESULTS
A total of 431 women were included in the study. The 
231 STD clinic attendees had a median age of 22 years 
(interquartile range (IQR) 22–26 years; range 18–56 
years); 23 and 13 women were ≥ 35 years and ≥ 40 years 
of age, respectively. The 200 women recruited at the 
Cancer Society had an age ranging from 35 to 64 years. 
All 431 participants were negative for T. vaginalis. C. 
trachomatis was detected in 37 (16%) of the STD clinic 
attendees and N. gonorrhoeae in none. Eighty-three 
(36%) of the women from the STD clinic were sympto-
matic and among these 18 (22%) had C. trachomatis, 28 
(34%) had bacterial vaginosis and 15 (18%) had positive 
Candida culture. C. trachomatis was associated with bac-
terial vaginosis in 7 cases and with Candida in 6 cases.
DISCUSSION
This study, in the Northern European country Iceland, 
evaluated the prevalence of trichomoniasis in a popula-
tion at risk for STDs and in women at the age of 35 
years and older who, in many studies, have had higher 
rates of T. vaginalis infection than younger women (3, 
8). No case of trichomoniasis was detected. In contrast, 
the prevalence of C. trachomatis in the STD attendees 
was 16%, which is higher than the rates of 3.8–8.6% 
reported from studies at STD clinics in Western and 
Northern Europe, the USA and Australia, where women 
were tested for both T. vaginalis and C. trachomatis 
(2, 4, 6, 9). This is not surprising, as the prevalence of 
diagnosed C. trachomatis infections in Iceland for the 
past 20 years has been among the highest in Europe, or 
up to 739 cases per 100,000 population (http://www.
landlaeknir.is/english/statistics/diseases/). Although this 
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high chlamydial prevalence is believed to be largely ex-
plained by widespread testing, it may also be an indicator 
of unprotected sex and liberal attitudes towards sexual 
activity; the mean age of first sexual intercourse is among 
the lowest in Europe, i.e. approximately 15 years (10). 
Such an environment should facilitate transmission of an 
STD, such as trichomoniasis, that is frequently asympto-
matic in both sexes and long-lasting in women (11). One 
plausible explanation for the rarity of trichomoniasis in 
Iceland is the exposure to metronidazole. T. vaginalis was 
a common finding in laboratories in Iceland 3–4 decades 
ago, and coincidental detection of the organism in urine 
specimens and in Pap smears, following the implementa-
tion of a nationwide screening programme in the 1960s, 
would have prompted metronidazole therapy. In addition, 
metronidazole has long been used for suspected bacterial 
vaginosis, whose symptoms may resemble trichomo-
niasis. A recent report from Australia described a high 
prevalence (20–30%) of trichomoniasis among women 
in the 1950s. After the introduction of metronidazole, 
in the 1960s, the prevalence declined steadily over the 
following 20 years and was below 1% in 1990 (12). 
Studies indicate that access to healthcare affects the 
prevalence of trichomoniasis. While the prevalence has 
been estimated at only 5.8% in Europe, in contrast to 
22% and 20.2% in the Americas and Africa, respectively 
(11), recent NAAT studies reveal socioeconomic and 
racial disparities within well-resourced countries. Thus, 
although prevalence is low, i.e. 0.016–3.6%, among 
women who attend STD clinics or physicians’ offices 
in Northern and Western Europe and Australia (4–6, 
9), a study at an English sexual health clinic revealed 
a significantly higher prevalence of trichomoniasis in 
black Caribbean women compared with white women, 
which may be partly explained by disparities in access 
to healthcare (5). Similarly, trichomoniasis was detected 
in 29.1% of black women attending an STD clinic in the 
USA, where access to healthcare is not universal (3). 
Risk analyses have indeed demonstrated significant as-
sociation of trichomoniasis with factors such as ethnicity 
(black race), lower educational level and poverty (3, 8).
However, the persistence of high rates of C. tracho-
matis infections in Iceland and other countries that 
provide universal access to healthcare, contrasts with 
the decline in trichomoniasis. The reasons for this are 
probably multifactorial and can only be hypothesized. 
For example, both specific and fortuitous detection of 
T. vaginalis in a number of tests have contributed to 
management of trichomoniasis before diagnosis of C. 
trachomatis infections, via culture and subsequently 
non-culture methods (13), became widely implemented. 
Before the highly sensitive NAATs were available, many 
C. trachomatis cases were also missed. Furthermore, 
most women in industrialized countries become sexually 
active in their late teens (10) when susceptibility to C. 
trachomatis infections is higher than in older women 
(13). This, together with the high number of sexual con-
tacts, including new contacts, and repeat infections after 
treatment, contributes to persistence of infection in the 
young population. In addition, C. trachomatis infections 
are more likely than trichomoniasis to be asymptomatic 
in women (8, 13). These asymptomatic infections can be 
detected mainly through screening or contact notification. 
However, the uptake of screening might not have been 
sufficiently high for long enough, and in most settings the 
contact notification is suboptimal. As suggested recently, 
autoinoculation in women of cervical C. trachomatis 
infection from the rectal site might also contribute to re-
peated detection of C. trachomatis in urogenital samples 
(14). In addition, whereas metronidazole therapy cures 
undiagnosed trichomoniasis when used for the most 
frequent vaginal disorder, bacterial vaginosis, no such 
benefits are associated with doxycycline, whose sole 
indication in female genital infections is C. trachomatis. 
There were a few limitations to our study. First, the T. 
vaginalis NAAT was performed 4 months after specimen 
collection, and unpublished experiments have shown that 
some proportion of positive specimens might become 
negative after 4 months despite storage at –80°C (15). 
Secondly, vaginal swabs are considered the optimal spe-
cimens for detection of T. vaginalis in women. Thus, it 
cannot be excluded that the urine specimens, as well as 
cervical smears collected in PreservCyt Solution liquid 
Pap, had a slightly lower sensitivity for T. vaginalis detec-
tion. However, both urine specimens and liquid cytology 
specimens are considered acceptable specimens for T. 
vaginalis detection using NAAT (1). 
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